SECuRE trial update: Another participant with undetectable PSA & negative PSMA PET
Sydney, Australia 23 February 2026 Highlights Another participant with metastatic castration-resistant prostate cancer (mCRPC) in the Cohort Expansion Phase (Phase II; 8 GBq of 67Cu-SAR-bisPSMA per cycle) of the SECuRE trial (NCT04868604)1 achieved undetectable disease as assessed by prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) positron emission tomography (PET). Undetectable disease by PSA was…